Safety, Efficacy and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis
Phase 3
- Conditions
- Juvenile Rheumatoid Arthritis (JRA)
- Registration Number
- JPRN-jRCT2080220565
- Lead Sponsor
- Abbott Japan Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Subjects who have a diagnosis of Polyarticular JRA by the ACR criteria.
Exclusion Criteria
Subject who is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method